Moderna最快周五向日本政府申请批准使用其新冠疫苗
《共同社》引述消息指,美国生物企业Moderna(MRNA.US)与武田药品,最快会於周五(5日)向日本厚生劳动省申请批准使用由Moderna研发的新冠疫苗。
日本政府已与该公司签订合同,将在6月底之前接受4,000万剂,9月底之前获得1,000万剂的供应。接种为间隔28天的两次,签约的供应量相当於2,500万人份。
武田药品工业正在日本人推进临床试验,以20岁以上的200人为对象调查Moderna疫苗的有效性和安全性,结果预计将在3月内被提交给厚劳省。
美国疾病控制和预防中心(CDC)称,严重的全身性剧烈过敏反应症状发生频率为每40万人中出现一例,是「极其罕见」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.